Infosys Files Antitrust Counterclaims In Trade Secrets Suit

Infosys has escalated its legal battle with Cognizant TriZetto Software Group by filing antitrust counterclaims in response to a Texas federal lawsuit accusing Infosys of misusing proprietary system access to develop competing healthcare software services. Infosys alleges Cognizant has engaged in monopolistic practices to stifle competition in the healthcare IT market.

Central Issue: Restrictive Access Agreements

At the center of the dispute are nondisclosure and access agreements (NDAAs) that Infosys signed to service clients using Cognizant’s TriZetto systems. Cognizant’s lawsuit, filed in August, claims Infosys breached those agreements and misused proprietary information to develop its Infosys Helix platform.

Infosys counters that these NDAAs form the backbone of Cognizant’s alleged monopolistic conduct. According to Infosys, Cognizant uses contractual restrictions to block competitors from developing complementary products, providing training, or freely operating in the market, forcing payors—such as hospitals and insurers—to overpay for outdated software like TriZetto’s Facets and QNXT systems.